Carisma Therapeutics, Inc.
CARM
$0.06
$0.019.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 52.63M | 10.77M | 19.96M | 19.63M | 20.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.63M | 10.77M | 19.96M | 19.63M | 20.27M |
| Cost of Revenue | 27.36M | 38.48M | 51.37M | 59.67M | 63.51M |
| Gross Profit | 25.28M | -27.72M | -31.40M | -40.04M | -43.24M |
| SG&A Expenses | 12.43M | 16.39M | 18.60M | 20.14M | 23.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.79M | 54.88M | 69.97M | 79.81M | 87.04M |
| Operating Income | 12.85M | -44.11M | -50.00M | -60.18M | -66.77M |
| Income Before Tax | 8.04M | -49.38M | -50.77M | -60.48M | -64.00M |
| Income Tax Expenses | -- | -- | -- | -- | -197.00K |
| Earnings from Continuing Operations | 8.04 | -49.38 | -50.77 | -60.48 | -63.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.04M | -49.38M | -50.77M | -60.48M | -63.80M |
| EBIT | 12.85M | -44.11M | -50.00M | -60.18M | -66.77M |
| EBITDA | 14.18M | -42.04M | -47.68M | -56.83M | -63.37M |
| EPS Basic | 0.19 | -1.18 | -1.22 | -1.46 | -1.56 |
| Normalized Basic EPS | 0.21 | -0.64 | -0.73 | -0.88 | -0.98 |
| EPS Diluted | 0.19 | -1.18 | -1.22 | -1.46 | -1.56 |
| Normalized Diluted EPS | 0.21 | -0.64 | -0.73 | -0.88 | -0.98 |
| Average Basic Shares Outstanding | 167.10M | 166.90M | 166.66M | 165.82M | 164.46M |
| Average Diluted Shares Outstanding | 167.25M | 166.90M | 166.66M | 165.82M | 164.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |